Sickle Cell Disease
Theravia’s clinical research is centered on sickle cell disease, with attention to treatment needs in paediatric patients and the management of chronic haematological symptoms. The funded study focuses on children aged 9 months to 11 years, reflecting interest in early-life disease care and age-appropriate therapy.
- Paediatric sickle cell disease
- Hydroxycarbamide treatment in children
- Haematology and red blood cell disorders
The sponsor’s research activity includes clinical evaluation of oral dispersible formulations used in children with sickle cell disease, supporting therapeutic development in paediatric haematology.
Pharmacokinetics and Drug Exposure
Theravia’s trial portfolio includes work in pharmacokinetics, with a focus on how hydroxycarbamide is handled in the body in young children. This area of interest supports understanding of drug exposure patterns in paediatric patients receiving twice-daily treatment.
- Population pharmacokinetic modelling
- Paediatric drug disposition
- Oral dispersible tablet pharmacology
Research in this domain is directed toward characterising medication behaviour in children and informing therapeutic use in paediatric haematology.
Paediatric Therapeutics
The sponsor is active in paediatric therapeutics, with particular attention to treatment options suitable for infants and children. The clinical programme reflects interest in formulations designed for young patients who require age-adapted administration.
- Child-friendly oral formulations
- Long-term treatment in children
- Age-specific medication use
These activities place emphasis on medicines intended for routine use in children living with chronic blood disorders.
Safety and Efficacy in Chronic Blood Disorders
Theravia’s research interests also include the clinical assessment of safety and efficacy in treatment for chronic haematological disease. The funded study examines outcomes relevant to ongoing care in children with sickle cell disease.
- Treatment tolerability
- Clinical response in paediatric patients
- Management of chronic anaemia-related disease
This area supports the development of therapies used in the clinical management of inherited blood disorders.
